UBS Reaffirms Their Buy Rating on Haleon PLC (HLN)
UBS analyst Guillaume Delmas maintained a Buy rating on Haleon PLC today and set a price target of p478.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Delmas is ranked #4946 out of 12160 analysts.
In a report released today, Barclays also maintained a Buy rating on the stock with a £4.15 price target.
Based on Haleon PLC’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of p2.74 billion and a net profit of p403 million. In comparison, last year the company earned a revenue of p2.78 billion and had a net profit of p303 million
Based on the recent corporate insider activity of 48 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of HLN in relation to earlier this year.
Read More on GB:HLN:
Disclaimer & DisclosureReport an Issue
- Haleon Shareholders Back All Resolutions at 2026 AGM, Endorsing Board and Capital Flexibility
- Haleon: Resilient Fundamentals and Strong Oral Health Growth Support Buy Rating and Unchanged $440 Price Target
- Haleon: Resilient Core Growth and Attractive Valuation Prompt Buy Rating, Price Target Maintained at $450
- Haleon publishes Q1 2026 trading update and schedules investor Q&A
- Haleon launches ‘For the Assist’ campaign
